- Alnylam Capital Expansion and Renovation - PMA Consultants
Alnylam Pharmaceuticals is managing an extensive capital expansion program The portfolio includes several hundred capital projects, with scope ranging from infrastructure expansions through the continued growth of research and manufacturing programs
- Luke Ward - Alnylam Pharmaceuticals | LinkedIn
· Experience: Alnylam Pharmaceuticals · Education: Columbia University in the City of New York · Location: Greater Boston · 500+ connections on LinkedIn View Luke Ward’s profile on LinkedIn, a
- Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an . . .
Alnylam has a strong and proven track record to ensure those who may benefit from RNAi therapeutics will have access to them, as outlined in the Company’s latest Patient Access Philosophy report Consistent with our Patient Access Philosophy, AMVUTTRA is priced in line with the value delivered
- Alnylam Issues 2021 Corporate Responsibility Report - Metro . . .
CAMBRIDGE, Mass – (BUSINESS WIRE)– Alnylam Pharmaceuticals, Inc (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2021 Corporate Responsibility Report
- Alnylam Announces Appointment of Elliott Sigal, M. D. , Ph. D . . .
CAMBRIDGE, Mass – (BUSINESS WIRE)– Alnylam Pharmaceuticals, Inc (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M D , Ph D , to its Board of Directors
- Alnylam Recognized by Science Magazine as Top Employer for . . .
CAMBRIDGE, Mass – (BUSINESS WIRE)– Alnylam Pharmaceuticals, Inc (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its third place ranking in Science magazine’s Top Employer Survey for 2023
- U. S. Transthyretin Amyloidosis Market Projected To Witness . . .
An in-depth review of company profiles, spotlighting major players and their strategic manoeuvres in the market's competitive arena Conclusive study concerning the expansion plot of U S Transthyretin Amyloidosis Treatment Marketplace for upcoming years
|